Related Experiment Videos
Ten years after the WHO classification for lung cancer: where are we?
1Division of Anatomic Pathology, Mayo Clinic, Rochester, MN.
Lung Cancer (Amsterdam, Netherlands)
|November 1, 1994
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2018
Temporal changes in the surgical pathology of prosthetic aortic valves: a study of 157 cases spanning 26 years (1970-1995).
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Pathologic interpretation of transbronchial biopsy for acute rejection of lung allograft is highly variable.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Prolonged cardiac allograft survival using iodine 131 after human sodium iodide symporter gene transfer in a rat model.
Transplantation proceedings·2010
Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes.
Lung cancer (Amsterdam, Netherlands)·2026
Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.
Lung cancer (Amsterdam, Netherlands)·2026
Adjuvant immunotherapy in resectable non-small cell lung cancer with nodal downstaging.
Lung cancer (Amsterdam, Netherlands)·2026
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands)·2026
First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial.
Lung cancer (Amsterdam, Netherlands)·2026